About VieCure
With the complexities of cancer care exploding due to the paradigm shift towards precision medicine, we saw a need for a platform that actively assists clinicians.
We call this Halo Intelligence.
Our Expertise
We are not a technology company. We are not a data company. We are a Cancer Care Company. We come by this space naturally.
Our executive team boasts over 130 years of cancer care experience, and our President, CEO was the founder of the world's first ever Oncology specific EMR.
We've learned from that experience, and are now building the tools for the future.
What is Halo Intelligence?
Halo Intelligence is the first whole knowledge system that brings together everything clinicians need to find the right treatment plan for every patient, every time.
It does this by distilling data from all aspects of the VieCure EcoSystem. The end result is a seamless marriage of artificial intelligence and the clinicians' own natural intelligence creating what we call, The Halo Effect.
Natural Intelligence
Natural intelligence is the ability for the human mind to process and organize inputs into actionable knowledge. Includes the ability to respond to less rational circumstances. Limited ability to process larger volumes of data.
Artifical Intelligence
Artificial intelligence uses computers to simulate natural intelligence and discernment. It can process large quantities of data but lacks the sensitivities and intuition that natural intelligence uses to fully understand the implications of its decisions.
Halo
Intelligence
Halo intelligence blends Natural Intelligence (Provider user and VieCure cancer knowledge base) and A.I. with discrete patient data to help clinicians make better-personalized decisions for every patient in real-time.
=
+
Our Mission
To ensure that every cancer patient lives their best life. Our focus is the patient.
We accomplish this by following our 4 values:
Agility; Urgency; Innovation; Impact.
We challenge the status quo and challenge you to ask yourself - are your software tools assisting you in helping cancer patients live their best lives?
Our Philosophy
We believe precision medicine, value based care, and NGS are the future of cancer care.
We don't seek out clients, but rather we're looking for partners who share that belief.
Cancer practices are still using tools built 20 to 30 years ago. Why? Do you believe there is a paradigm shift in Oncology? Do you believe your current tools were built for that shift?
Introducing Halo Intelligence
Our Leadership
Combining excellence in cancer care, software, artificial intelligence, and business.
Gerry Hogue
Chairman, President, and CEO
Founder of OpTx Corp
30+ Yrs. Cancer Leadership
Former SVP Elekta North America
Gerry is the founder of VieCure, and presently serves as its President & CEO. He has spent many years working in the field of enabling technologies for cancer care, and is excited to now be leading the charge in genomics-based, personalized medicine that empowers cancer patients and their families.
Michael G. Power
Chief Business Development Officer
Former EVP Cancer Care Ontario
Former CEO Cancer Research Institute
Former SVP Elekta Global Strategic
Michael is the Chief Business Development Officer. He helped found VieCure and leads the Global Business Development portfolio. Michael has more than twenty-years of executive level experience in cancer medicine and is a NHL draftee of the Edmonton Oilers Hockey Club.
Dr. Fred Ashbury
Chief Scientific Officer
30+ Years of Cancer Leadership
Former Senior Executive with Cancer Care Ontario
Former CSO with OpTx Corp
Fred is a co-founder and Chief Scientific Officer at VieCure. He is responsible for developing and maintaining VieCure’s oncology clinical content, genomic-science knowledge identification and codification, and the design and implementation of the treatment strategy rules that underpin our platform. He was the co-founder for Intelligent Improvement Consultants, a healthcare management consulting firm. He is a former senior executive with the National Cancer Institute of Canada, Cancer Care Ontario, and the Alberta Cancer Board, OpTx Corporation, and BridgeSite Clinical Research.